This study aims to evaluate the effects of niraparib in those who have received neoadjuvant
chemotherapy and subsequent interval debulking surgery, with or without hyperthermic
intraperitoneal chemotherapy, and would also explore if there are any biomarkers, other than
BRCA / HRD status and platinum sensitivity, that may help to identify those who may benefit
from PARPi especially those who are HRD negative.
Despite cytoreductive surgery and platinum-based chemotherapy, about 70% of patients with
advanced ovarian cancer recur in the first 2 - 3 years. PARPi has been shown to be prolong
survival in primary advanced ovarian cancer. However its role in neoadjuvant setting has not
been fully evaluated.
ovarian tumors, Ovarian Cancer, cancer of the ovary, Ovarian Function, Recurrent Ovarian Cancer, ovarian carcinomas, cancer, ovarian, Ovarian disorder, cancer ovarian
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.